Castle Biosciences
350 articles about Castle Biosciences
-
Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma
4/29/2020
Published Recently in the Journal of the American Academy of Dermatology
-
Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020
4/27/2020
Castle Biosciences, Inc. announced that it will release its financial results for the first quarter ended March 31, 2020, after the close of market on Monday, May 11, 2020.
-
Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
4/6/2020
Castle Biosciences, Inc. today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020, at 3:30 p.m. Eastern time. A live audio webcast of
-
Castle Biosciences Appoints Miles Harrison to Board of Directors
4/2/2020
Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced that Miles Harrison has been appointed to the board of directors, effective immediately, expanding the size of the board to eight members.
-
Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk
4/1/2020
Castle Biosciences, Inc. (Nasdaq: CSTL), today announced the publication of a systematic review and meta-analysis of four study cohorts demonstrating that the DecisionDx®-Melanoma test is an independent, significant predictor of recurrence and metastatic risk in patients with invasive cutaneous melanoma.
-
Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic
3/27/2020
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin and eye cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today posted to its website results from a survey performed by the Collaborative Ocular Oncology Group (COOG) for the purpose of providing a current practices survey for clinicians regarding management of patients diagnosed with uveal melanoma and other ocular tumors during the COVID-19 pandemic.
-
Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma
3/26/2020
Castle Biosciences, Inc., today announced the publication of a multicenter, prospective study demonstrating that DecisionDx ® -UM test results significantly impacted treatment plan recommendations for patients with uveal melanoma (U
-
Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results
3/10/2020
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the fourth quarter and twelve months ended December 31, 2019.
-
Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma
3/5/2020
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that the United States Patent and Trademark Office (USPTO) issued the Company its first U.S. patent related to the DecisionDx®-Melanoma gene expression profile test for patients with cutaneous melanoma
-
Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020
2/25/2020
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the fourth quarter and year-ended December 31, 2019, after the close of market on Tuesday, March 10, 2020.
-
Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2/12/2020
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Wednesday, February 26, 2020, at 1:00 p.m. Eastern time.
-
Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma
1/20/2020
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of clinical utility data for its cutaneous squamous cell carcinoma (SCC) prognostic test, DecisionDx®-SCC, for patients diagnosed with high-risk cutaneous SCC.
-
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019
1/9/2020
Q4 2019 DecisionDx-Melanoma test report volume increased 37% compared to Q4 2018
-
Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology
12/30/2019
The results show that the DecisionDx-Melanoma test achieves a higher level of evidence than determined by major organizations that publish guidelines on melanoma management.
-
Castle Biosciences Added to NASDAQ Biotechnology Index
12/18/2019
Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that the Company was recently added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to the market open on Monday, December 23, 2019.
-
Castle Biosciences Announces Time Change for Presentation at the Evercore ISI Second Annual HealthCONx
12/3/2019
Castle Biosciences, Inc. announced that its presentation at the Evercore ISI Second Annual HealthCONx Conference is now scheduled for 11:45 a.m. Eastern time on Thursday, December 5, 2019, in Boston.
-
Castle Biosciences to Present at Upcoming Investor Conferences
11/20/2019
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at the following upcoming investor conferences
-
Castle Biosciences Reports Third Quarter 2019 Results
11/11/2019
Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018
-
Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk
10/31/2019
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of results from a study validating a newly developed nomogram tool that combines information from the DecisionDx®-Melanoma test with clinicopathologic features to improve prediction of patients’ risk of melanoma recurrence.
-
Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting
10/29/2019
Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced the presentation of a development update and validation data for its cutaneous squamous cell carcinoma prognostic test, DecisionDx®-SCC.